비호지킨림프종 치료제 시장 규모, 점유율, 성장 분석 : 치료 종류별, 약물 종류별, 투여 경로별, 적응증별, 지역별 - 산업 예측(2025-2032년)
Non-Hodgkin Lymphoma Therapeutics Market Size, Share, and Growth Analysis, By Therapeutic Type, By Drug class, By Administration Route, By Indication, By Region - Industry Forecast 2025-2032
상품코드:1738068
리서치사:SkyQuest Technology Consulting Pvt. Ltd.
발행일:2025년 05월
페이지 정보:영문 197 Pages
라이선스 & 가격 (부가세 별도)
한글목차
비호지킨림프종 치료제 세계 시장 규모는 2023년에 52억 달러로 평가되었으며, 예측 기간(2025-2032년) 동안 CAGR 6.9%로, 2024년 55억 6,000만 달러에서 2032년에는 94억 8,000만 달러로 성장할 전망입니다.
세계 비호지킨림프종(NHL) 치료제 시장은 고령화와 조기 발견을 가능하게 하는 진단 기술의 발전으로 인한 NHL 발병률 증가에 힘입어 크게 성장하고 있습니다. 이러한 환자 수의 증가는 효과적인 치료법에 대한 수요 증가로 이어져 제약회사와 의료 서비스 제공자들은 새로운 치료법 개발에 집중하고 있습니다. 또한, 연구개발에 대한 투자도 급증하여 시장 확대를 촉진하고 있습니다. 특히 암세포를 효과적으로 표적화하여 파괴하는 면역요법, 특히 키메라 항원 수용체(CAR) T 세포 치료의 발전은 주목할 만한 추세입니다. 이러한 혁신적인 치료법은 환자의 예후를 개선하고 맞춤형 요법으로의 전환을 촉진하여 비호지킨림프종 치료제 부문의 성장을 더욱 촉진하고 있습니다.
목차
소개
조사 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장 가정과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porters 분석
주요 시장 인사이트
핵심성공요인
경쟁 정도
주요 투자 기회
시장 생태계
시장 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
비호지킨림프종 치료제 시장 규모 : 치료 종류별 & CAGR(2025-2032년)
시장 개요
화학요법
면역요법
표적요법
방사선 치료
비호지킨림프종 치료제 시장 규모 : 약물 종류별 & CAGR(2025-2032년)
시장 개요
단클론항체
화학요법제
브루톤형 티로신 키나아제 억제제
면역조절제
비호지킨림프종 치료제 시장 규모 : 투여 경로별 & CAGR(2025-2032년)
시장 개요
정맥내
경구
피하
비호지킨림프종 치료제 시장 규모 : 적응증별 & CAGR(2025-2032년)
시장 개요
미만성 대세포형 B세포 림프종
여포성 림프종
맨틀세포 림프종
버킷 림프종
비호지킨림프종 치료제 시장 규모 : 지역별 & CAGR(2025-2032년)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5개사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채용한 전략
최근의 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업 개요
기업 상세
제품 포트폴리오 분석
기업 부문별 점유율 분석
매출 전년비 비교(2022-2024년)
주요 기업 개요
Roche(Switzerland)
Novartis(Switzerland)
Gilead Sciences(USA)
Bristol-Myers Squibb(USA)
AbbVie(USA)
Merck & Co.(USA)
AstraZeneca(United Kingdom)
Sanofi(France)
Bayer AG(Germany)
Johnson & Johnson(USA)
Pfizer(USA)
Eli Lilly and Company(USA)
Takeda Pharmaceutical Company Limited(Japan)
Genmab(Denmark)
Seagen Inc.(USA)
Teva Pharmaceutical Industries Ltd.(Israel)
Kyowa Kirin Co., Ltd.(Japan)
Spectrum Pharmaceuticals Inc.(USA)
Autolus Therapeutics(UK)
Immuneel Therapeutics Private Limited(India)
결론과 제안
ksm
영문 목차
영문목차
Global Non-Hodgkin Lymphoma Therapeutics Market size was valued at USD 5.2 billion in 2023 and is poised to grow from USD 5.56 billion in 2024 to USD 9.48 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).
The global Non-Hodgkin Lymphoma (NHL) therapeutics market is experiencing significant growth, driven by the rising incidence of NHL, primarily due to an aging population and advancements in diagnostic technologies that enable earlier detection. This increasing patient base is resulted in a higher demand for effective treatments, prompting pharmaceutical companies and healthcare providers to focus on developing new therapeutic options. Additionally, there is a surge in research and development investments, stimulating market expansion. A notable trend is the advancement of immunotherapy, particularly Chimeric Antigen Receptor (CAR) T-cell therapies, which effectively target and destroy cancer cells. These innovative treatments improve patient outcomes, fostering a shift toward personalized regimens and further fueling growth within the NHL therapeutics sector.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Hodgkin Lymphoma Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Non-Hodgkin Lymphoma Therapeutics Market Segments Analysis
Global Non-Hodgkin Lymphoma Therapeutics Market is segmented by Therapeutic Type, Drug class, Administration Route, Indication and region. Based on Therapeutic Type, the market is segmented into Chemotherapy, Immunotherapy, Targeted Therapy and Radiation Therapy. Based on Drug class, the market is segmented into Monoclonal Antibodies, Chemotherapeutic Agents, Bruton's Tyrosine Kinase Inhibitors and Immunomodulators. Based on Administration Route, the market is segmented into Intravenous, Oral and Subcutaneous. Based on Indication, the market is segmented into Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma and Burkitt Lymphoma. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Non-Hodgkin Lymphoma Therapeutics Market
The global non-Hodgkin lymphoma therapeutics market is primarily driven by the rising incidence of non-Hodgkin lymphoma, largely attributed to an aging population and various lifestyle factors. As the number of diagnoses continues to climb, there is an escalating need for advanced treatment solutions, including immunotherapies, chemotherapy, and targeted therapies. This heightened demand for innovative treatment options not only reflects the urgency in addressing patients' needs but also propels significant growth in the market, further encouraging research and development efforts aimed at improving patient outcomes and expanding therapeutic possibilities in combating this form of cancer.
Restraints in the Global Non-Hodgkin Lymphoma Therapeutics Market
The growth of the Global Non-Hodgkin Lymphoma Therapeutics market faces substantial obstacles, particularly in developing regions where there is a limited understanding of non-Hodgkin lymphoma. The challenges associated with early diagnosis significantly impede market progression, as insufficient healthcare infrastructure and lack of diagnostic resources create delays in identifying and treating the condition. This lack of timely intervention adversely impacts the demand for therapeutic options, ultimately constraining market expansion in these underserved areas. Addressing these awareness and infrastructure gaps is crucial for enabling better access to treatments and enhancing market potential in the long term.
Market Trends of the Global Non-Hodgkin Lymphoma Therapeutics Market
The Global Non-Hodgkin Lymphoma (NHL) therapeutics market is experiencing a significant shift towards immunotherapy, particularly with the rise of CAR-T cell therapies. This innovative approach leverages the body's immune response to effectively target and eliminate lymphoma cells, showing remarkable efficacy in patients with relapsed or refractory cases. The increasing approval of these advanced therapies, coupled with ongoing research and clinical trials, underscores a growing acceptance and demand within the healthcare community. As a result, the market is projected to expand rapidly, driven by enhancements in treatment outcomes, patient quality of life, and the potential for personalized medicine strategies in NHL management.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Global Non-Hodgkin Lymphoma Therapeutics Market Size by Therapeutic Type & CAGR (2025-2032)
Market Overview
Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Global Non-Hodgkin Lymphoma Therapeutics Market Size by Drug class & CAGR (2025-2032)
Market Overview
Monoclonal Antibodies
Chemotherapeutic Agents
Bruton's Tyrosine Kinase Inhibitors
Immunomodulators
Global Non-Hodgkin Lymphoma Therapeutics Market Size by Administration Route & CAGR (2025-2032)
Market Overview
Intravenous
Oral
Subcutaneous
Global Non-Hodgkin Lymphoma Therapeutics Market Size by Indication & CAGR (2025-2032)
Market Overview
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Burkitt Lymphoma
Global Non-Hodgkin Lymphoma Therapeutics Market Size & CAGR (2025-2032)
North America (Therapeutic Type, Drug class, Administration Route, Indication)
US
Canada
Europe (Therapeutic Type, Drug class, Administration Route, Indication)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Therapeutic Type, Drug class, Administration Route, Indication)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Therapeutic Type, Drug class, Administration Route, Indication)
Brazil
Rest of Latin America
Middle East & Africa (Therapeutic Type, Drug class, Administration Route, Indication)
